Gland Pharma has debuted at Rs 1701.00 on the BSE, up by 201 points or 13.40% from its issue price of Rs 1500.00.
The scrip is currently trading at Rs 1790.85, up by 290.85 points or 19.39% from its issue price. It has touched a high and low of Rs 1850.00 and Rs 1701.00 respectively. So far 6.92 lakh shares were traded on the counter.
The offering, which was open for subscription between November 09, 2020 and November 11, 2020, was subscribed 2.06 times. The issue price was fixed at Rs 1500 per share i.e. at upper end of price band of Rs 1490-1500 apiece.
Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in over 60 countries, including the US, Canada, Australia and India.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: